Gilead Sciences (NASDAQ:GILD) Rating Increased to Outperform at Raymond James

Gilead Sciences (NASDAQ:GILDGet Free Report) was upgraded by equities researchers at Raymond James from a “market perform” rating to an “outperform” rating in a research note issued on Monday, Marketbeat Ratings reports. The firm presently has a $93.00 target price on the biopharmaceutical company’s stock. Raymond James’ price target indicates a potential upside of 39.45% from the stock’s current price.

Several other research firms have also recently issued reports on GILD. Morgan Stanley reduced their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Maxim Group decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Thursday, June 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $84.00.

Check Out Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Trading Up 0.2 %

NASDAQ GILD opened at $66.69 on Monday. The firm has a market cap of $83.09 billion, a PE ratio of 185.25, a price-to-earnings-growth ratio of 2.83 and a beta of 0.18. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a 50-day moving average of $66.08 and a 200-day moving average of $72.07.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same period in the prior year, the business posted $1.37 earnings per share. Gilead Sciences’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, sell-side analysts forecast that Gilead Sciences will post 3.75 EPS for the current year.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.29% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Institutional & Family Asset Management LLC increased its holdings in Gilead Sciences by 47.1% in the 2nd quarter. Institutional & Family Asset Management LLC now owns 2,084 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 667 shares in the last quarter. DNB Asset Management AS grew its stake in shares of Gilead Sciences by 47.1% in the second quarter. DNB Asset Management AS now owns 290,803 shares of the biopharmaceutical company’s stock worth $19,952,000 after acquiring an additional 93,165 shares during the period. Modus Advisors LLC raised its holdings in shares of Gilead Sciences by 10.8% during the second quarter. Modus Advisors LLC now owns 9,810 shares of the biopharmaceutical company’s stock valued at $673,000 after purchasing an additional 960 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Gilead Sciences by 72.6% during the second quarter. Massmutual Trust Co. FSB ADV now owns 4,487 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 1,887 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Gilead Sciences by 56.0% in the second quarter. GAMMA Investing LLC now owns 9,940 shares of the biopharmaceutical company’s stock worth $682,000 after purchasing an additional 3,567 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.